WARNING! For educational purposes: We do not endorse any of these combinations. This page will always be 'work in progress'. It is extremely important to be safe at all times!

Chart versions

English

Portuguese

German

Polish

General information

Substance class description

Psychedelics

2C-T-x is a moderate MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin).-A inhibitor, can cause SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Syndrome when combined with monoamine releasers, SSRIs or other MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibitors.
- https://www.ncbi.nlm.nih.gov/pubmed/15801832

αMT is a reversible MAOIMonoamine oxidase inhibitor are drugs that inhibit the action of monoamine oxidase in the brain and so allow monoamines to accumulate. in higher doses (the danger rises exponentially as αMT doses approach 150 mg due to increased monoamine release and increased MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibition), can cause SerotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. Syndrome when combined with monoamine releasers, SSRIs or other MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). inhibitors.

5-MeO substituted tryptamines are SNRIs or SNDRIs and therefore should not be combined with other reuptake inhibitors or MAOIs.

Opioids

Tramadol acts as a μ-opioid receptor agonistA substance that initiates a physiological response when combined with a receptor., serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. releasing agent (SRA), serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. and norepinephrine reuptake inhibitor (SNRISerotonin–Norepinephrine Reuptake Inhibitor), NMDAN-methyl-D-aspartate receptor. NMDA antagonists are often dissociatives. receptor antagonistA substance that interferes with or inhibits the physiological action of another., 5-HT2C receptor antagonistA substance that interferes with or inhibits the physiological action of another., 5 nicotinic acetylcholine receptor antagonistA substance that interferes with or inhibits the physiological action of another., TRPV1 receptor agonistA substance that initiates a physiological response when combined with a receptor., and M1 and M3 muscarinic acetylcholine receptor antagonistA substance that interferes with or inhibits the physiological action of another.. It can cause seizures, serotoninA monoamine neurotransmitter, biochemically derived from tryptophan, that is primarily found in the gastrointestinal (GI) tract, platelets, and central nervous system (CNS) of humans and animals. It is a well-known contributor to feelings of well-being. syndrome and even death when combined with certain stimulants and other reuptake inhibitors.

Specific combinations with references (work in progress)

LSD & DMT

"Low doses antagonized the effects of both hallucinogens, whereas larger doses enhanced their effects."

http://www.ncbi.nlm.nih.gov/pubmed/3006089

http://deepblue.lib.umich.edu/bitstream/handle/2027.42/26285/0000370.pdf

LSD & GHB/GBL

http://www.ncbi.nlm.nih.gov/pubmed/16483730

LSD & Opioids

http://www.ncbi.nlm.nih.gov/pubmed/547279

http://www.ncbi.nlm.nih.gov/pubmed/3006089

"Low doses antagonized the effects of both hallucinogens, whereas larger doses enhanced their effects."

http://www.ncbi.nlm.nih.gov/pubmed/3006089

http://deepblue.lib.umich.edu/bitstream/handle/2027.42/26285/0000370.pdf

GHB/GBL & MAOIs

No study, but MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). B inhibitors should enhance the effects, no interaction with MAOMonoamine Oxidase, an enzyme that catalyses the metabolism of many drugs (e.g., DMT, dopamine and serotonin). A.